ADC Therapeutics S.A. (ADCT) Balance Sheet

The consistent negative retained earnings, which reached negative $1.7B in 2026Q1, indicate that the business model remains fundamentally dependent on external financing to bridge the gap between high operating costs and insufficient product revenue. This trajectory suggests that without a significant inflection in ZYNLONTA sales or a successful pipeline milestone, the company faces an increasingly constrained capital structure.

The sharp increase in debt levels warrants close monitoring, as the company's negative equity position leaves little room for balance sheet flexibility. Investors should consider whether this leverage is a bridge to profitability or a sign of mounting pressure to fund ongoing clinical trials amidst a competitive oncology landscape.

While the current ratio suggests an ability to cover short-term obligations, the underlying cash position of $231.0M is being depleted by the company's intensive R&D and SG&A requirements. This liquidity profile implies that the firm remains highly sensitive to the timing of milestone payments and potential future capital raises.

The absence of significant tangible assets underscores the high-risk nature of the business, as the company's valuation is entirely dependent on the clinical and commercial success of its PBD platform. This structure implies that any failure in clinical trial readouts could lead to rapid impairment of the firm's perceived value, as there is little physical collateral to support the balance sheet.